Zhejiang Conba Pharmaceutical (600572.SH) subsidiary's musk tongxin pill new indication clinical trial application approved.

Zhejiang Conba Pharmaceutical (600572.SH) announced that its wholly-owned subsidiary Inner Mongolia Zhejiang Conba Pharmaceutical Co., Ltd. (referred to as "Inner Mongolia Zhejiang Conba Pharmaceutical") recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for a new indication of Musk Venison Dripping Pills. The new indication applied for this time is for heart failure with preserved ejection fraction (TCM syndrome of qi deficiency and blood stasis), with the administration route being oral. It is reported that Toxin Heart Pill Musk Venison Dripping Pills are a traditional Chinese medicine independently developed and produced by Inner Mongolia Conba Pharmaceutical, approved for marketing in 2008, with the main functions being aromatically invigorating qi and promoting blood circulation, relieving blood stasis and pain. It is used for stable effort-induced angina pectoris of coronary heart disease, syndrome of qi deficiency and blood stasis in traditional Chinese medicine, with symptoms including chest pain, chest tightness, palpitations, shortness of breath, fatigue, and weakness.